Physician profile
Weyman Lam
NPI 1225442130
$30,066.61
in general payments reported to CMS, 2019-2025
41 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $999 · 2020: $1,951 · 2021: $3,015 · 2022: $3,553 · 2023: $4,281 · 2024: $4,159 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,272 · Education: $305 · Consulting Fee: $51.16 · Travel and Lodging: $16.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,904.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,272.00 |
| Education | $304.83 |
| Consulting Fee | $51.16 |
| Travel and Lodging | $16.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $8,399.37 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $5,742.98 | 2019-2025 | |
| Csl Behring | $2,395.21 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,828.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,733.72 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Regeneron Healthcare Solutions, INC. | $1,621.50 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $1,041.92 | 2019-2025 | Xolair |
| Alk-Abello, INC | $834.17 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Blueprint Medicines Corporation | $800.93 | 2023-2025 | Ayvakit |
| Grifols USA, LLC | $685.81 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $661.48 | 2020-2025 | |
| Pfizer INC. | $610.56 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $534.24 | 2021-2025 | |
| Pharming Healthcare, INC. | $517.96 | 2020-2025 | Ruconest |
| Amgen INC. | $469.56 | 2022-2025 | Tezspire |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weyman Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.